% IMPORTANT: The following is UTF-8 encoded. This means that in the presence
% of non-ASCII characters, it will not work with BibTeX 0.99 or older.
% Instead, you should use an up-to-date BibTeX implementation like “bibtex8” or
% “biber”.
@ARTICLE{Altomare:916865,
author = {Altomare, Daniele and Collij, Lyduine and Caprioglio,
Camilla and Scheltens, Philip and van Berckel, Bart N. M.
and Alves, Isadora Lopes and Berkhof, Johannes and de Gier,
Yvonne and Garibotto, Valentina and Moro, Christian and
Poitrine, Léa and Delrieu, Julien and Payoux, Pierre and
Saint-Aubert, Laure and Molinuevo, José Luis and
Grau-Rivera, Oriol and Gispert, Juan-Domingo and
Minguillón, Carolina and Fauria, Karine and Sanchez, Marta
Felez and Rădoi, Andreea and Drzezga, Alexander and Jessen,
Frank and Escher, Claus and Zeyen, Philip and Nordberg,
Agneta and Savitcheva, Irina and Jelic, Vesna and Walker,
Zuzana and Lee, Ho-Yun and Lee, Lean and Demonet,
Jean-François and Plaza Wuthrich, Sonia and Gismondi,
Rossella and Farrar, Gill and Barkhof, Frederik and
Stephens, Andrew W. and Frisoni, Giovanni B. and Consortium,
AMYPAD},
title = {{D}escription of a {E}uropean memory clinic cohort
undergoing amyloid‐{PET}: {T}he {AMYPAD} {D}iagnostic and
{P}atient {M}anagement {S}tudy},
journal = {Alzheimer's and dementia},
volume = {19},
number = {3},
issn = {1552-5260},
address = {Hoboken, NJ},
publisher = {Wiley},
reportid = {FZJ-2023-00157},
pages = {844-856},
year = {2023},
abstract = {Introduction: AMYPAD Diagnostic and Patient Management
Study (DPMS) aims to investigate the clinical utility and
cost-effectiveness of amyloid-PET in Europe. Here we present
participants' baseline features and discuss the
representativeness of the cohort.Methods: Participants with
subjective cognitive decline plus (SCD+), mild cognitive
impairment (MCI), or dementia were recruited in eight
European memory clinics from April 16, 2018, to October 30,
2020, and randomized into three arms: ARM1, early
amyloid-PET; ARM2, late amyloid-PET; and ARM3,
free-choice.Results: A total of 840 participants (244 SCD+,
341 MCI, and 255 dementia) were enrolled.
Sociodemographic/clinical features did not differ
significantly among recruiting memory clinics or with
previously reported cohorts. The randomization assigned
$35\%$ of participants to ARM1, $32\%$ to ARM2, and $33\%$
to ARM3; cognitive stages were distributed equally across
the arms.Discussion: The features of AMYPAD-DPMS
participants are as expected for a memory clinic population.
This ensures the generalizability of future study
results.Keywords: Alzheimer's; PET; amyloid; dementia;
memory clinic population; mild cognitive impairment;
subjective cognitive decline.},
cin = {INM-2},
ddc = {610},
cid = {I:(DE-Juel1)INM-2-20090406},
pnm = {5252 - Brain Dysfunction and Plasticity (POF4-525) / 5253 -
Neuroimaging (POF4-525)},
pid = {G:(DE-HGF)POF4-5252 / G:(DE-HGF)POF4-5253},
typ = {PUB:(DE-HGF)16},
pubmed = {35715930},
UT = {WOS:000812481000001},
doi = {10.1002/alz.12696},
url = {https://juser.fz-juelich.de/record/916865},
}